Senhwa Completes CX-5461 Phase 1b Trial Enrollment
TAIPEI, Taiwan — August 25, 2026 Senhwa Biosciences announced that it has completed patient enrollment in its Phase 1b...
PARP Inhibitor
Advertisement
IMPACT Therapeutics Licenses Senaparib to Pharmanovia
SHANGHAI, July 31, 2026 IMPACT Therapeutics announced an exclusive licensing agreement with Pharmanovia, granting the global specialty pharmaceutical company...
Pfizer Inc. Wins FDA Priority Review for Prostate Cancer Therapy
NEW YORK, July 22, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Design at ESMO 2026
COPENHAGEN, Denmark, June 18, 2026 Allarity Therapeutics, Inc. announced the presentation of a Trial-in-Progress poster for its ongoing Phase...
Myriad CDx Test Approved to Guide Ovarian Cancer Therapy
SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Pfizer TALZENNA XTANDI Boost Survival in Prostate Cancer
NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...
Allarity Therapeutics Secures $20M to Advance Stenoparib
TARPON SPRINGS, Fla., March 6, 2026 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful closing of...
Advertisement
